Microba Life Sciences (ASX:MAP) FCF Margin % : -406.17% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Microba Life Sciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Microba Life Sciences's Free Cash Flow for the six months ended in Dec. 2023 was A$-13.29 Mil. Microba Life Sciences's Revenue for the six months ended in Dec. 2023 was A$3.27 Mil. Therefore, Microba Life Sciences's FCF Margin % for the quarter that ended in Dec. 2023 was -406.17%.

As of today, Microba Life Sciences's current FCF Yield % is -27.25%.

The historical rank and industry rank for Microba Life Sciences's FCF Margin % or its related term are showing as below:

ASX:MAP' s FCF Margin % Range Over the Past 10 Years
Min: -354.43 Med: -273.75 Max: -262.79
Current: -354.43

During the past 2 years, the highest FCF Margin % of Microba Life Sciences was -262.79%. The lowest was -354.43%. And the median was -273.75%.

ASX:MAP's FCF Margin % is ranked worse than
86.49% of 222 companies
in the Medical Diagnostics & Research industry
Industry Median: -11.09 vs ASX:MAP: -354.43

Microba Life Sciences FCF Margin % Historical Data

The historical data trend for Microba Life Sciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microba Life Sciences FCF Margin % Chart

Microba Life Sciences Annual Data

Trend

Jun22

Jun23

FCF Margin %

-262.79

-284.70

Microba Life Sciences Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	-	-	-257.42	-302.63	-406.17

Competitive Comparison of Microba Life Sciences's FCF Margin %

For the Diagnostics & Research subindustry, Microba Life Sciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Microba Life Sciences's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Microba Life Sciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Microba Life Sciences's FCF Margin % falls into.

Microba Life Sciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Microba Life Sciences's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-15.431	/	5.42
	=	-284.70 %

Microba Life Sciences's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-13.294	/	3.273
	=	-406.17 %

Microba Life Sciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of Microba Life Sciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Microba Life Sciences (ASX:MAP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Microba Life Sciences Ltd (ASX:MAP) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000

Website

https://www.microba.com

Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome which includes delivering gut microbiome testing services globally to consumers, clinicians, and researchers. The company's segment includes Testing Services, and Research and Development.

Microba Life Sciences (ASX:MAP) Headlines

No Headlines